Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-20

Study Completion Date

2020-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is an urgent need to evaluate interventions that can prevent the infection with SARS-CoV 2 of healthcare workers at risk. Melatonin is an inexpensive and safe product with protective effect in both bacterial and viral infections likely due to its anti-inflammatory and anti-oxidative effects. This randomized controlled trial seeks to evaluate is efficacy as a prophylaxis in healthcare workers exposed to the virus in their clinical practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19

NCT04568863

COVID-19 SARS-CoV 2 Coronavirus Infection

COMPLETED PHASE2

Effects of Melatonin on Insomnia Symptoms in Older Adults

NCT00230737

Sleep Initiation and Maintenance Disorders

COMPLETED PHASE2

Clinical Trial on a Food Supplement With Melatonin and Herbal Products to Improve Sleep Quality

NCT05459272

Sleep Disorders

UNKNOWN NA

Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19

NCT04470297

Covid19 Lung Injury

UNKNOWN PHASE2

A Novel Inhaled Formulation of Melatonin to Treat Adults With Insomnia: Efficacy Study

NCT06802913

Insomnia

RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Healthcare workers are at an increased risk of acquiring COVID-19 due to an increased exposure to the virus and global personal protective equipment shortages. Preventing the infection of healthcare workers is critical the current epidemic situation when healthcare systems are under extreme pressure. There is a lack of evidence surrounding potential preventive strategies to decrease the incidence of COVID-19 among healthcare workers.

Melatonin, an endogenous hormone involved in circadian rhythm control, is an inexpensive and safe product that has shown protective effects in bacterial and viral infections likely due to its anti-inflammatory and anti-oxidative effects.

SARS-CoV 2 seems to relatively spare younger children and those who are infected develop the severe forms of the disease very rarely. Peak melatonin serum levels are higher in younger children and decrease with age. These levels are also higher in women, specially during pregnancy, who also seem to be less affected by the virus when compared to men.

The investigators hypothesize that elevating peak melatonin levels to a range similar to that of children by administering 2 mg of melatonin daily might prevent the infection with SARS-CoV 2 among exposed healthcare workers. The investigators also hypothesize that among those who develop the disease melatonin might prevent the more severe forms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 SARS-CoV 2 Coronavirus Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Melatonin

2 mg of melatonin orally before bedtime for 12 weeks

Group Type EXPERIMENTAL

Melatonin 2mg

Intervention Type DRUG

2 mg of prolonged release melatonin tablets per os (P.O.) before bedtime for 12 weeks

Placebo

Identically looking placebo orally before bedtime for 12 weeks

Group Type PLACEBO_COMPARATOR

Placebo oral tablet

Intervention Type DRUG

Identically looking placebo tablets P.O. before bedtime for 12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Melatonin 2mg

2 mg of prolonged release melatonin tablets per os (P.O.) before bedtime for 12 weeks

Intervention Type DRUG

Placebo oral tablet

Identically looking placebo tablets P.O. before bedtime for 12 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

circadin 2 mg Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthcare workers from the public and private Spanish hospital network at risk of SARS-CoV 2 infection
* Not having a previous COVID19 diagnosis
* Not having experienced COVID19 symptoms from March 1st 2020 until randomization
* Understanding the purpose of the trial and not having taken any pre-exposure prophylaxis (PrEP) including HIV PrEP from March 1st 2020 until randomization
* Having a negative SARS-CoV 2 CRP before randomization
* Having a negative urinary pregnancy test in the previous 7 days for premenopausal women
* Premenopausal women and males with premenopausal couples must commit to using a high efficiency anticonceptive method

Exclusion Criteria

* HIV infection
* Active hepatitis B infection
* Renal failure (CrCl \< 60 mL/min/1.73 m2) or need for hemodialysis
* Osteoporosis
* Myasthenia gravis
* Retinitis pigmentosa
* Bradycardia (less than 50 bpm)
* Weight less than 40 Kg
* Treatment with drugs that prolong the QT interval for more than 7 days in the last month before randomization including: azithromycin, cisapride, methadone, droperidol, sotalol, quinidine, clarithromycin, haloperidol...
* Hereditary intolerance to galactose, Lapp lactase deficiency or glucose or galactose malabsorption
* Treatment with fluvoxamine
* Treatment with benzodiazepines or benzodiazepine analogues such as zolpidem, zopiclone or zaleplon
* Pregnancy
* Breastfeeding
* History of potentially immune derived diseases such as: lupus, Crohn's disease, ulcerative colitis, vasculitis or rheumatoid arthritis
* Insulin-dependent diabetes mellitus
* Known history of hypersensitivity to the study drug or any of its components
* Patients that should not be included in the study at the judgment of the research team

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No